350 related articles for article (PubMed ID: 17409911)
1. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Kaneda H; Tamura K; Kurata T; Uejima H; Nakagawa K; Fukuoka M
Lung Cancer; 2004 Nov; 46(2):247-54. PubMed ID: 15474673
[TBL] [Abstract][Full Text] [Related]
3. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
4. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Yang CH; Shih JY; Chen KC; Yu CJ; Yang TY; Lin CP; Su WP; Gow CH; Hsu C; Chang GC; Yang PC
Cancer; 2006 Oct; 107(8):1873-82. PubMed ID: 16989002
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Lee DH; Han JY; Kim HT; Lee JS
Lung Cancer; 2006 Sep; 53(3):339-45. PubMed ID: 16824646
[TBL] [Abstract][Full Text] [Related]
7. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
Lee DH; Han JY; Yu SY; Kim HY; Nam BH; Hong EK; Kim HT; Lee JS
J Thorac Oncol; 2006 Nov; 1(9):965-71. PubMed ID: 17409980
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
[TBL] [Abstract][Full Text] [Related]
9. [Predictive factors of gefitinib response and survival in Chinese patients with local advanced or metastatic non-small cell lung cancer].
Lin L; Zhang L; Zhao H; Lin L; Wu X; Zhang Y; Guan Z
Zhongguo Fei Ai Za Zhi; 2007 Oct; 10(5):411-7. PubMed ID: 21126411
[TBL] [Abstract][Full Text] [Related]
10. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
12. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Mohamed MK; Ramalingam S; Lin Y; Gooding W; Belani CP
Ann Oncol; 2005 May; 16(5):780-5. PubMed ID: 15728108
[TBL] [Abstract][Full Text] [Related]
13. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K; Goto K
Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
[TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
Konishi J; Yamazaki K; Kinoshita I; Isobe H; Ogura S; Sekine S; Ishida T; Takashima R; Nakadate M; Nishikawa S; Hattori T; Asahina H; Imura M; Kikuchi E; Kikuchi J; Shinagawa N; Yokouchi H; Munakata M; Dosaka-Akita H; Nishimura M
Anticancer Res; 2005; 25(1B):435-41. PubMed ID: 15816608
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Satouchi M; Negoro S; Funada Y; Urata Y; Shimada T; Yoshimura S; Kotani Y; Sakuma T; Watanabe H; Adachi S; Takada Y; Yatabe Y; Mitsudomi T
Br J Cancer; 2007 Apr; 96(8):1191-6. PubMed ID: 17387341
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.
Yang CT; Hung JY; Lai CL; Hung HC; Lai YF; Lin MC; Shieh JM; Huang MS
Kaohsiung J Med Sci; 2010 Jan; 26(1):1-7. PubMed ID: 20040466
[TBL] [Abstract][Full Text] [Related]
20. Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Matsuura K; Kudoh S; Yoshimura N; Kimura T; Mitsuoka S; Hirata K; Yoshikawa J; Iwao H
Osaka City Med J; 2006 Jun; 52(1):1-8. PubMed ID: 16986358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
